Targeted Oncology

, Volume 5, Issue 1, pp 53–58 | Cite as

Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment

  • Nathalie Lassau
  • Mohamed Chebil
  • Linda Chami
  • Sophie Bidault
  • Elizabeth Girard
  • Alain Roche


Dynamic contrast-enhanced ultrasonography (DCE-US) is a new functional technique enabling a quantitative assessment of solid tumor perfusion using raw linear data. DCE-US allows the calculation of parameters as slope of wash-in or area under the curve (AUC) representing, respectively, blood flow or blood volume. Reduction in tumor vascularization can easily be detected in responders after 1 or 2 weeks and is correlated with progression-free survival and overall survival in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). DCE-US is supported by the French National Cancer Institute (INCa), which is currently studying the technique in metastatic breast cancer, melanoma, colon cancer, gastrointestinal stromal tumors and renal cell carcinoma, as well as in primary hepatocellular carcinoma, to establish the optimal perfusion parameters and timing for quantitative anticancer efficacy assessments. Currently 490 patients are included in 20 centers and the preliminary results on 400 patients with 1,096 DCE-US demonstrated that AUC could be a robust parameter to predict response.


Doppler-ultrasound Contrast agent Angiogenesis Evaluation of treatment 


Conflict of Interest statement

No funds were received to support this article.


  1. 1.
    Rehman S, Jayson GC (2005) Molecular imaging of antiangiogenic agents. Oncologist 10:92–103CrossRefPubMedGoogle Scholar
  2. 2.
    Schwartz L (2005) Imaging in drug discovery: emerging roles and challenges. In: Plenary session, RSNA Program, Chicago, IL, 27 November-2 December 2005, p 35Google Scholar
  3. 3.
    Benjamin R (2006) Response of gastrointestinal stromal tumors to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. J Clin Oncol 24(18S):9506Google Scholar
  4. 4.
    Cosgrove D (2003) Angiogenesis imaging—ultrasound. Br J Radiol 76:S43–S49CrossRefPubMedGoogle Scholar
  5. 5.
    Lassau N, Koscielny S, Opolon P, De Baere T, Peronneau P, Leclere J, Roche A (2001) Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 36:50–55CrossRefPubMedGoogle Scholar
  6. 6.
    Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S et al (2002) Phase II trial of thalidomide in renal cell carcinoma. Ann Oncol 13:1029–1035CrossRefPubMedGoogle Scholar
  7. 7.
    Greis C (2004) Technology overview: Sonovue (Bracco, Milan). Eur Radiol 14(Suppl 8):P11–P15PubMedGoogle Scholar
  8. 8.
    Lassau N, Lamuraglia M, Vanel D, Le Cesne A, Chami L, Jaziri S et al (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 16:1054–1060CrossRefPubMedGoogle Scholar
  9. 9.
    Lassau N, Lamuraglia M, Chami L, Leclère J, Bonvalot S, Terrier P et al (2006) Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol 187:1267–1273CrossRefGoogle Scholar
  10. 10.
    Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclère J, Roche A, Lassau N (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42:2472–2479CrossRefPubMedGoogle Scholar
  11. 11.
    Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E et al (2007) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13:18011809CrossRefGoogle Scholar
  12. 12.
    Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F et al (2005) Recommendations for the management of GIST patients. Bull Cancer 92:907–918PubMedGoogle Scholar
  13. 13.
    Choi H, Faria S, Benjamin R, Podoloff D, Macapinlac H, Charnsangavej C et al (2002) Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIS) with CT and PET: a quantitative analysis. Proceedings of the RSNA Scientific Program, Chicago, p 583Google Scholar
  14. 14.
    De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M (2005) Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 11:6171–6176CrossRefPubMedGoogle Scholar
  15. 15.
    Le Cesne A, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F et al (2005) Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales. Hepato-Gastro 12:377–389Google Scholar
  16. 16.
    Lamuraglia M, Le Cesne A, Chami L, Bonvalot S, Terrier P, Tursz T, Roche A, Lassau N (2006) Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). J Clin Oncol 24(18S):9539Google Scholar
  17. 17.
    Le Cesne A, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, Bui B, Nguyen B, Bugat R, Chayvialle JA, Rougier P, Bouche O, Bonichon F, Lassau N, Vanel D, Nordlinger B, Stoeckle E, Meeus P, Coindre JM, Scoazec JY, Emile JF, Ranchere D, Blay JY (2006) Recommendations for the management of gastro-intestinal stromal tumors. Ann Pathol 26(3):231–234CrossRefPubMedGoogle Scholar
  18. 18.
    Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673–682CrossRefPubMedGoogle Scholar
  19. 19.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  20. 20.
    Soria JC, Lazar V, Lassau N, Pena C, Massard C, Robert C, Koscielny S, Deutsch E, Zafarana E, Armand JP (2007) Sorafenib (S) and dacarbazine (D) combination in patients with advanced malignant solid tumors: phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US). J Clin Oncol 25(18S):3556Google Scholar
  21. 21.
    Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier B (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast –enhanced ultrasonography. Clin Cancer Res 16(4):1216–1225Google Scholar
  22. 22.
    Lassau N, Koscielny S, Chebil M, Chami L, Bendjilali R, Roche A, Escudier B, Le Cesne A, Soria J (2009) Functional imaging using DCE-US: which parameters for the early evaluation of antiangiogenetic therapies? 45th Annual meeting of America Society of Clinical Oncology, Nov 2009, Chicago, IL, USAGoogle Scholar
  23. 23.
    Lassau N, Lacroix J, Aziza R, Villegrain V, Taieb S, Koscielny S (2009) French Multicentric Prospective Evaluation of Dynamic Contrast-enhanced Ultrasound (DCE-US) for the evaluation of the antiangiogenic treatments. 95th Radiological Society of North America, Nov 2009, Chicago, IL, USAGoogle Scholar
  24. 24.
    Pellier J, Chevalier J, Koscielny S, Bonastre J, Benatsou B, Lassau N (2009) Methodological Study to Assess the Evolution of the Quality of Dynamic Contrast-enhanced Ultrasound in a Large National Multicentric Study 95th Radiological Society of North America, Nov 2009, Chicago, IL, USAGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Nathalie Lassau
    • 1
    • 2
  • Mohamed Chebil
    • 1
    • 2
  • Linda Chami
    • 1
    • 2
  • Sophie Bidault
    • 1
  • Elizabeth Girard
    • 1
  • Alain Roche
    • 1
    • 2
  1. 1.Imaging DepartmentInstitut Gustave RoussyVillejuifFrance
  2. 2.Imaging Department and IR4M, UMR8081, Ultrasonography UnitInstitut Gustave-RoussyVillejuifFrance

Personalised recommendations